PVLA

Latest SEC Filings & News for PVLA

2 most recent filings and news items mentioning PVLA. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day

curl "https://api.brieftape.com/v1/tickers/PVLA/news?limit=20"

Pull PVLA filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day

RegulatoryJun 16, 2026Neutral

Palvella increases equity plan share reserve by 750,000 shares

Palvella Therapeutics amended its 2024 Equity Incentive Plan to increase available shares for issuance to 4,090,639 shares, approved by stockholders on June 10, 2026. The increase addresses anticipated future equity compensation needs for employee retention and incentives.

View filing at SEC.gov →

RegulatoryMay 20, 2026Positive

Palvella presents positive Phase 3 SELVA and Phase 2 TOIVA data for QTORIN rapamycin

Palvella Therapeutics announced clinical trial results showing 100% of SELVA participants aged 6-11 years improved on primary endpoint, with QTORIN rapamycin demonstrating potential as first FDA-approved therapy for microcystic lymphatic malformations and cutaneous venous malform

View filing at SEC.gov →

AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.